Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.
Although the relationship between antipsychotic medication, particularly second-generation antipsychotics (SGAs), and metabolic disturbance is increasingly accepted, there is an important, but little recognised, potential interaction between this and the other important serious adverse effect of neuroleptic malignant syndrome (NMS). We report a case of a 35-year old female who developed new onset type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure following treatment with a SGA for a first manic episode. The history is strongly suggestive of concurrent NMS. This case raises important questions about non-ketotic, hyperosmolar diabetic coma with antipsychotics, the possible association between hyperglycaemia and hyperthermia, and the direction of causality in this, the recognition of either syndrome when they co-exist and management issues in such patients. These questions are considered in the context of currently available literature.
Ahuja
N
N
Wallsend Community Mental Health Team, Sir GB Hunter Hospital, Wallsend, Tyne and Wear, UK. niraj.ahuja@ncl.ac.uk
Palanichamy
N
N
Mackin
P
P
Lloyd
Aj
A
D058186:Acute Kidney Injury / Q000139:chemically induced; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced; D005260:Female; D006801:Humans; D006944:Hyperglycemic Hyperosmolar Nonketotic Coma / Q000139:chemically induced*; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D000077152:Olanzapine
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine